

May 31, 2024

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroze Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	---

Dear Sir/Madam,

**Sub: Master Service Agreement (MSA) signed between Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD) and TheraNym Biologics Private Limited, a wholly owned subsidiary – Reg.,**

**Ref: Our letters dated September 01, 2022, October 11, 2023 and March 28, 2024**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

Further to our disclosure letters dated September 1, 2022, October 11, 2023 and March 28, 2024 informing about (i) expansion of the biologics manufacturing facilities and exploring the possibilities to enter into contract manufacturing operations (“CMO”) for biologicals, (ii) execution of a limited Letter of Intent (“LOI”) between CuraTeQ Biologics Private Limited (“CuraTeQ”), a wholly owned subsidiary of the Company along with its subsidiary(ies), and Merck Sharp & Dohme Singapore Trading Pte. Ltd. and its affiliates (“MSD”), whereby the parties intended to conclude the negotiations by March 31, 2024, and (iii) Extension of the timelines to conclude the negotiations by May 31, 2024.

In this regard, we wish to inform you that TheraNym Biologics Pvt. Ltd. (a wholly owned subsidiary of the Company and an affiliate of CuraTeQ), and MSD, signed a Master Service Agreement (MSA) effective on May 31, 2024.

Additional disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure**.

Please take the above information on record.

Thanking you,

Yours faithfully,  
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Encl.: Annexure

## AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**Annexure**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Description</b>
i	Name of the entity(ies) with whom agreement/ JV is signed;	TheraNym Biologics Private Limited, a wholly owned subsidiary of the Company (TheraNym) with Merck Sharpe & Dohme Singapore Trading Pte. Ltd (MSD).
ii	Area of agreement/JV;	For expansion of the biologics manufacturing facilities of TheraNym situated at Sy no: 379/P, Borapatla(V), Hathnoora Mandal, Medak District, Borapatla, TS and exploring the possibilities to enter into contract manufacturing operations (“CMO”) for biologicals.
iii	Domestic / international;	Both domestic & international
iv	Share exchange ratio / JV ratio;	Not applicable
v	Scope of business operation of agreement / JV;	To enter contract manufacturing operations (CMO) for biologicals and augmenting the business prospects in this area.
vi	Details of consideration paid / received in agreement / JV;	Not applicable
vii	Significant terms and conditions of agreement / JV in brief;	TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement.
viii	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
ix	Size of the entity(ies);	Theranyam will invest around Rs.1,000 crores for establishing manufacturing facility with large scale bioreactors for any mammalian cell culture product and a vial filling isolator line for commercial drug product manufacturing upto 25-30 mn vials per annum.
x	Rationale and benefit expected.	To enter contract manufacturing operations (CMO) for biologicals and augmenting the business prospects in this area.

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

[www.aurobindo.com](http://www.aurobindo.com)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)